Adjuvant Chemotherapy’s Limited Benefit in Node-Negative Pancreatic Cancer

In a Danish cohort study emulating a randomized controlled trial, researchers assessed adjuvant chemotherapy’s impact on node-negative (PN0) and node-positive (PN+) pancreatic cancer survival after surgery. Among PN0 patients, adjuvant therapy showed no significant 2-year survival difference (-2.2%). For PN+ individuals, a 9.9% improvement in 2-year survival was noted. Median overall survival was 24.9 months with adjuvant and 15.0 months without. The study suggests limited survival benefit from adjuvant chemotherapy in node-negative pancreatic cancer cases.